More Videos
- Could The Credit Crisis Help Pfizer?
- Biotech Bonanza For ImClone & Dendreon
- Dendreon, ImClone & Pfizer: Your Emails
- Lilly's "Secret" (About ImClone) Is Out--Or Is It?
- Oktoberfest For ImClone & Dendreon (Update On Mystery Bid)
- The Waiting Game Continues For Lilly & ImClone
- Will Lilly Pull An Upset (Like Oregon State Over USC) With Effient?
- Medtronic Has A Real "Bead" On Mardi Gras Time (Updates)
- Bristol Vs. ImClone Heats Up As Icahn Gets Nastier
- Merck Manual: May "Help" Patients But What About Its Stock?
- Bloggers Becoming Part Of College Football "Rankings"
- Apple's Big Mo: "Losses" Are Only Real When They Are Realized
- Bull Stampede, Tuesday?
- NFL's Troy Aikman: Advice For The Business Athlete
- Video: China Launches Short Selling
- Cramer Thinks Dow Drops Further
- More Tales Of Mortgage Meltdown--And What Do We Call This?
- Financial Psychiatrist: Panic Means Opportunity
- Fund Honcho Ackman: Wachovia Bidding War Good for Banks
- How Bad Can Crisis Get? Watch Credit, Not Stocks
- JPMorgan Froze Lehman Assets Ahead of Bankruptcy
- Like J.P. Morgan, Warren E. Buffett Braves a Crisis
- US Job Market Weakens in September
- Shaky Economy May Last For a While
- Reliant to Seek Strategic Alternatives
- Brazil Leads LatAm Markets Down
- Treasury Prices Storm Ahead Amid Safety Stampede
- In Money Markets, Lending Remains Non-Existent
Text Size 
 |
] put out a press release this morning announcing that an unidentified institutional investor is going to buy eight million shares and warrants to buy as much as another eight million for a total infusion of $47 million. DNDN says it will use the money to "fund our commercialization activities for Provenge," among other things. Provenge is a therapeutic vaccine for prostate cancer that is in the middle of a crucial clinical trial.
related content |
Back in February I blogged about Morgan Stanley and a hedge fund, Visium Asset Management, taking a combined 16.5 percent stake in DNDN. Big investors like that have 45 days to disclose their positions to the Securities and Exchange Commission, so the identity of Dendreon's secret lover could be revealed in the not-too-distant future.
Dendreon can be a very volatile stock. It has a huge short interest or shares that belong to investors who are hoping the price will fall. This is not an investment for the faint of heart. But obviously another one of the "big boys" has a strong ticker.
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes